Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.
about
Improving the risk assessment of lipophilic persistent environmental chemicals in breast milkRelationships of chemical concentrations in maternal and cord blood: a review of available data.The Navigation Guide - evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth.Maternal exposure to perfluorinated chemicals and reduced fecundity: the MIREC study.Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK)Investigation of the Effects of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) on Apoptosis and Cell Cycle in a Zebrafish (Danio rerio) Liver Cell Line.Variability and epistemic uncertainty in water ingestion rates and pharmacokinetic parameters, and impact on the association between perfluorooctanoate and preeclampsia in the C8 Health Project population.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women.Perfluoroalkyl Acids in Maternal Serum and Indices of Fetal Growth: The Aarhus Birth Cohort.A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancyIntegration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.Association between perfluoroalkyl substances and thyroid stimulating hormone among pregnant women: a cross-sectional study.Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study.A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans.Perfluoroalkyl and polyfluoroalkyl substances and human fetal growth: a systematic review.Perfluorinated Alkyl Substances: Emerging Insights Into Health Risks.Brief Report: Plasma Concentrations of Perfluorooctane Sulfonamide and Time-to-pregnancy Among Primiparous Women.Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model.Estimating Methylmercury Intake for the General Population of South Korea Using Physiologically Based Pharmacokinetic Modeling.Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.Breastfeeding as an Exposure Pathway for Perfluorinated Alkylates.Physiologically based pharmacokinetic modeling of perfluoroalkyl substances in the human body
P2860
Q26849356-5A9B01FA-0C4A-4AC3-AD6C-F705855C3F40Q30805001-51DC3B5E-40B8-42FA-9015-7D013C9B48D7Q34275367-2CFEE451-03D2-49E4-939A-8FE2779E2AA6Q35076573-009CF580-BC35-414F-9435-D84866A9088AQ36350881-E119BE82-FB21-4B70-83AC-CFC7C5934BA5Q36403684-E50409EB-87E5-4111-B3DE-D97633C27DA7Q36601073-9FB112C4-842C-4B9E-B9BD-1DC6BC8F08D3Q36706781-82914DC8-5549-400E-AB51-09ACEB3721CCQ36707568-6E665FB5-9943-4E40-B59B-E80653D50FBBQ36968190-E623E95C-3950-434F-8D2B-F64E2ED89B40Q37207844-B32F9362-906B-46C2-B748-08843DC6A5B3Q37228208-70C6D6C8-48CD-431C-8B41-94D03AEF6484Q37357430-D11D3145-34FE-4368-8A6B-DF74DB873B6CQ37408761-0785C942-5470-4721-8638-F61797722383Q38209158-23262FC5-CCD3-488B-BBC0-9AA37D87FA47Q38265262-86ECBB4F-F82F-4C7D-8151-77235B6B43B3Q38530449-BC0A6675-37AB-444F-8B7F-5F13D9AB22DCQ40712408-17E2C83B-005E-4ECB-98FE-3B06503AC202Q47578009-8B3231B6-D4FB-41FB-B871-C7180FCD687FQ50115995-549B2F82-BFB2-48AD-87E4-E052D6FBE22CQ50457888-9F39D3B6-2E76-4F06-9518-0DAE46CC56D0Q50597914-BDEED044-BB35-4EB8-BBD2-EC36A1CB466FQ50974898-A582DCB8-182A-4200-A4B3-F580FAEBFACBQ53378653-A4D6661D-8C6A-4799-9430-051D5883CC21Q57266432-FDAEFCFB-BFA5-41CB-869D-408688CD6826
P2860
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Development of PBPK models for ...... ncy and lactation life stages.
@ast
Development of PBPK models for ...... ncy and lactation life stages.
@en
type
label
Development of PBPK models for ...... ncy and lactation life stages.
@ast
Development of PBPK models for ...... ncy and lactation life stages.
@en
prefLabel
Development of PBPK models for ...... ncy and lactation life stages.
@ast
Development of PBPK models for ...... ncy and lactation life stages.
@en
P2093
P2860
P1476
Development of PBPK models for ...... ncy and lactation life stages.
@en
P2093
Anne E Loccisano
Harvey J Clewell
Jerry L Campbell
P2860
P356
10.1080/15287394.2012.722523
P577
2013-01-01T00:00:00Z